Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (2021 - 2025)

Indivior Pharmaceuticals has reported Shares Outstanding over the past 5 years, most recently at $125.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $125.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $125.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $125.0 million, changed 0.0%.
  • Shares Outstanding for Q4 2025 was $125.0 million at Indivior Pharmaceuticals, roughly flat from $125.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for INDV hit a ceiling of $702.0 million in Q4 2021 and a floor of $125.0 million in Q4 2024.
  • Median Shares Outstanding over the past 5 years was $130.0 million (2024), compared with a mean of $181.8 million.
  • Biggest five-year swings in Shares Outstanding: plummeted 80.63% in 2022 and later increased 0.74% in 2023.
  • Indivior Pharmaceuticals' Shares Outstanding stood at $702.0 million in 2021, then plummeted by 80.63% to $136.0 million in 2022, then grew by 0.74% to $137.0 million in 2023, then dropped by 8.76% to $125.0 million in 2024, then changed by 0.0% to $125.0 million in 2025.
  • The last three reported values for Shares Outstanding were $125.0 million (Q4 2025), $125.0 million (Q3 2025), and $125.0 million (Q2 2025) per Business Quant data.